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Case series
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Hyperthermic intraperitoneal chemotherapy (HIPEC) is a key component of treatment in non-gynecologic
peritoneal surface malignancies. As many as 10–15% of patients with a gastrointestinal primary malignancy will
present with carcinomatosis. Maximal cytoreductive surgery directly aﬀects the prognosis of patients. The
routine inclusion of hysterectomy with bilateral salpingo-oophorectomy during these procedures optimizes
cytoreduction despite negative pre-operative imaging and ﬁndings at the time of surgery. In this case series, we
review twenty non-gynecologic cancer patients who underwent cytoreductive surgery with concurrent hysterectomy and bilateral salpingo-oophorectomy and HIPEC at our institution.

1. Introduction
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal
chemotherapy (HIPEC) are eﬀective treatment modalities for non-gynecologic peritoneal surface malignancies. Peritoneal carcinomatosis is
present in 10–30% of patients with gastrointestinal cancer at the time of
initial surgery and usually is associated with a poor prognosis (Harmon
and Sugarbaker, 2005). The goal of HIPEC is to target remaining microscopic residual tumor following an optimal complete resection. In
the last decade, randomized clinical trials have demonstrated signiﬁcant improved overall survival in patients with gastric cancer who
underwent CRS followed by HIPEC compared to cytoreduction or systemic therapy alone (Yang et al., 2011; Rudloﬀ et al., 2014). Although
utilizing HIPEC for the treatment of colorectal cancer remains controversial, the highest median overall survival to date was seen in a
recent multicenter clinical trial of metastatic colorectal cancer patients
after treatment with CRS and HIPEC of 41.7 months (Quenet and Roca,
2018). CRS and HIPEC have also shown clinical beneﬁt for patients
with peritoneal carcinomatosis originating from the appendix (El
Halabi et al., 2012) and malignant peritoneal mesothelioma (Turaga
et al., 2017). It remains as the only potential cure for patients with
pseudomyxoma peritonei (Benhaim et al., 2019). CRS improved both
overall survival and progression free survival in colon cancers metastatic to the ovaries. Although statistical signiﬁcance was not reached in
breast or gastric cancer with ovarian metastasis, a trend towards
⁎

improved beneﬁt was noted (Ayhan et al., 2005).
Both intraoperative and postoperative disease burden predicts
overall survival. The Peritoneal Cancer Index (PCI) quantiﬁes disease
burden according to amount and location using intraoperative direct
visualization. Higher PCI values are associated with decreased survival
following CRS and HIPEC (Chu et al., 1989). To evaluate the extent of
surgical debulking, Glehen and Gilly created the CC score that deﬁnes
residual tumor diameter: no visible residual tumor (CC-0), less than
2.5 mm (CC-1), 2.5 mm to 2.5 cm (CC-2), and greater than 2.5 cm (CC3). Their studies indicated that the beneﬁts of HIPEC diminished as the
CC score increased, and CC score was the most signiﬁcant independent
prognostic factor for patient survival (Glehen et al., 2004). As expected,
patients undergoing incomplete cytoreduction faced increased morbidity with poorer survival (Lee et al., 2020).
Our institution takes a unique approach to patients with non-gynecologic peritoneal carcinomatosis. Female patients deemed optimal
candidates for CRS and HIPEC undergo pre-operative counseling with
both surgical oncology and gynecologic oncology. Using a shared decision-making model with the patient, hysterectomy and bilateral salpingo-oophorectomy are recommended as part of the cytoreductive
eﬀort regardless of whether gynecologic organ involvement is suspected preoperatively. To date, no literature has examined the role for
concurrent hysterectomy and bilateral salpingo-oophorectomy in these
non-gynecologic peritoneal carcinomatosis patients undergoing HIPEC.
In this case series, we describe the demographics, pre-operative,
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intraoperative, and ﬁnal pathology ﬁndings, the operative times, and
immediate postoperative outcomes at our institution.

Table 1
Demographic Characteristics.
Characteristics

No. Patients (%)

Total
Age Group
< 52 years
52+ years
Race
Caucasian
African American
Other
Cancer Type
Mucinous Appendiceal
Colonic Adenocarcinoma
Gastric Adenocarcinoma
Urachal Mucinous
Mesothelioma
Small Bowel Adenocarcinoma
Pathologic Grade
1
2
3
Unknown
BMI (kg/m2)
15–25
26–35
36–45
46–55

20 (1 0 0)
Range (18–75 years)
8 (40.0)
12 (60.0)

2. Methods
A retrospective chart review was performed on twenty consecutive
patients presenting to the Markey Cancer Center between August 1,
2018, and February 28, 2020, who underwent cytoreductive surgery
with concurrent hysterectomy and bilateral salpingo-oophorectomy
and HIPEC for a non-gynecologic malignancy at the University of
Kentucky. This review was conducted in accordance with the US
Common Rule and approved by the Institutional Review Board (IRB).
Demographic variables, such as age, race, BMI, preoperative assessment, intraoperative ﬁndings, ﬁnal pathologic diagnosis, and 30-day
surgical outcomes were included in the analysis.
Our institution utilizes an open approach to CRS through a midline
laparotomy incision. Initial exploration quantiﬁes PCI. All female patients, regardless of gross disease, undergo the following procedures:
resection of the greater and lesser omentum, appendectomy, cholecystectomy, hysterectomy, bilateral salpingo-oophorectomy, and tumor
debulking with the goal of achieving complete resection of all visible
disease. A closed system technique is used for administration of HIPEC
with the Genesis Medical System. The abdomen is warmed with hyperthermic saline to 43 °C and chemotherapy is infused and perfused
for 30–90 min with simultaneous agitation of the abdomen. We typically administer cisplatin for 60 min for gastric cancer and mitomycin C
for 90 min in appendiceal and colorectal primaries. Following administration, the abdomen is rinsed with three liters of saline, the abdomen
re-opened and irrigated, and the deﬁnitive visceral reconstruction
performed (Riggs et al., 2020).

15 (75.0)
2 (10.0)
3 (15.0)
9
3
3
1
2
2

(45.0)
(15.0)
(15.0)
(5.0)
(10.0)
(10.0)

5
6
3
6

(25.0)
(30.0)
(15.0)
(30.0)

6
7
6
1

(30.0)
(35.0)
(5.61)
(5.0)

not included in the graded complications. This patient had recurrent
pseudomyxoma peritonei that had ﬁstulized into the uterus. No other
intraoperative complications were noted.
In the peri- and post-operative course, nine patients (45%) recovered uneventfully. Most of the complications recorded were grade III. Five patients had grade III complications, and one had a grade IV
complication. One patient who had extensive diaphragmatic resection
required a chest tube on postoperative day two for a pneumothorax
occurrence. One patient developed pancytopenia felt to be secondary to
sequestered chemotherapy perfusate ﬂuid in the pleural cavity that
resolved after interventional radiology guided thoracentesis and growth
factor support. One patient was noted to have a small pleural eﬀusion
postoperatively that was expectantly managed and later developed a
right upper quadrant hematoma requiring aspiration but never required
a transfusion. The two other grade III complications are described
further with their readmissions. The grade IV complication occurred in
a patient who developed pneumonia following an aspiration event on
postoperative day four requiring ICU care and intubation, resulting in a
sixteen-day postoperative hospital stay.
In the subsequent six-week period following discharge from the
initial hospitalization, four patients required readmission. One patient
was readmitted with dehydration from high colostomy output. Another
patient was readmitted three weeks postoperatively with a peri-splenic
abscess that resolved with drain placement. A third patient was found
to have a strangulated hernia three weeks postoperatively and underwent an exploratory laparotomy with mesh repair. The ﬁnal patient was
readmitted three weeks postoperatively for a paralytic ileus treated
expectantly and a pelvic ﬂuid collection managed with antibiotics.

3. Results
The cohort was comprised of twenty female patients aged
18–75 years old (mean 52 years). Reﬂective of Kentucky demographics,
race was predominantly Caucasian (15/20, 75%). The most common
cancer type was mucinous appendiceal adenocarcinoma (9/20, 45%).
Several of the mucinous appendiceal subtypes were considered lowgrade appendiceal neoplasms (4/9, 44.4%). BMI ranged from
17.3–49.2 kg/m2 (mean 30.24 kg/m2). Demographic characteristics of
all subjects are shown in Table 1.
Nine patients (9/20, 45%) had evidence of gynecologic organ disease on pre-operative assessment, either from imaging studies with
positron emission tomography (PET) or computed tomography (CT)
scan or from pre-operative assessment via diagnostic laparoscopy to
determine eligibility for HIPEC. Thirteen patients (13/20, 65%) had
gross involvement of the gynecologic organs at the time of surgery, and
sixteen (16/20, 80%) had conﬁrmation of disease on ﬁnal pathology. Of
the eleven patients with negative pre-operative assessment, ﬁve had
gross visible disease at the time of surgery with positive ﬁnal pathologic
analysis. An additional three had microscopic disease on ﬁnal pathology that was not visible preoperatively or intraoperatively as shown
in Fig. 1.
The average PCI of the cases was 7.9 with seven patients having a
PCI ≥ 10. At the completion of surgery, eighteen patients (90%) had a
CC-0 score, and two patients (10%) had a score of CC-1 at the time of
HIPEC. Mean estimated blood loss was 152.5 mL (range 50–500 mL) for
the non-gynecologic portion and 106.5 mL (range 25–400 mL) for the
gynecologic portion of the cases. These ﬁndings are displayed in
Table 2. The mean operative time of the cases was 481 min (range
271–790 min). Patients were discharged home after a mean of 7 days
(range 4–16 days).
Complications are summarized using the Clavien-Dindo
Classiﬁcation system in Table 3 (Clavien et al., 2009). One intraoperative cystotomy occurred during the completion of the hysterectomy as part of the oncologic resection for her disease burden and is

4. Discussion
This descriptive case series examines the potential to maximize
cytoreductive surgery eﬀorts for non-gynecologic cancers undergoing
HIPEC by including a gynecologic oncologist for a planned hysterectomy and bilateral salpingo-oophorectomy, regardless of preoperative imaging or intraoperative ﬁndings at the time of surgery.
Overall, eighty percent of patients in our series had metastasis to gynecologic organs. Even in patients with a negative preoperative assessment for gynecologic involvement, 72.7% (8 of 11 patients) were
2
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Fig. 1. Pelvic organ involvement by non-gynecologic malignancies ﬂowsheet.

mentally prepared to undergo that portion of the surgery.
In non-gynecologic cancers, HIPEC and CRS have an estimated
morbidity of 30–50%, mortality of 1–5%, with a mean operative time of
388–550 min depending on the extent of peritoneal procedures (Baratti
et al., 2010). A positive correlation between duration of surgery,
number of peritonectomy procedures and resections, and number of
suture lines correlated with combined grade III-IV morbidities. Duration of surgery was the most common predictor of morbidity and was
associated with pancreatitis, cardiovascular toxicity, wound sepsis,
systemic sepsis, bile leak, and deep vein thrombosis. In a study by
Stephens, et al., their average patient had 2.1 prior surgeries and a PCI
of 19 with the majority (150/183) having appendiceal primary as the
source (Stephens et al., 1999).
In our patients, mean operative time including the hysterectomy
and bilateral salpingo-oophorectomy was 481 min, which is similar to
that quoted in prior studies. Our perioperative and postoperative
complications are also similar to what is quoted in the literature, suggesting that the addition of a planned hysterectomy and bilateral salpingo-oophorectomy with each case may not add to the overall morbidity of the procedure. The inclusion of a hysterectomy added an
average of 106 mL of blood loss to the case. The only event directly
linked to hysterectomy in our series was a cystotomy created during en
bloc resection of the uterus with tumor that was not unexpected given
her disease extent and required oncologic resection. A second patient
requiring readmission three weeks postoperatively for ileus was found
to have a pelvic ﬂuid collection requiring antibiotics that could have
been secondary to the hysterectomy portion of the case. Our patients
had an average PCI of 7.9 with seven of twenty patients having a
PCI ≥ 10. The PCI of the patients in the prior studies mentioned was
19, suggesting a higher surgical complexity, although this does not take
into consideration the surgical and medical history of our patients prior
to the operation.
The key limitation to this study is its retrospective nature and case
series design. Based on our practice approach, a control group that did
not have concurrent hysterectomy and bilateral salpingo-oophorectomy
is unavailable for comparison of outcomes. However, this is the ﬁrst
study to take a deeper look into concurrent hysterectomy and bilateral
salpingo-oophorectomy in non-gynecologic cancer cases. Eighty percent of patients in our series had gynecologic organ involvement including both expected and unexpected ﬁnal pathologic ﬁndings. Prior
studies would suggest that maximal cytoreduction leads to improved
outcomes, but further prospective trials would be needed to fully understand the survival impact of hysterectomy and bilateral salpingooophorectomy in this setting.

Table 2
Surgical Demographics.
Characteristics

No. Patients (%)

Total
PCI values
Range (mean)
Cytoreduction Score
CC-0
CC-1
Operative Time
Range (mean), minutes
Estimated blood loss, average in cc (range)
Gynecologic
Non-gynecologic
Length of hospital stay
Range (mean), days

20 (1 0 0)
0–22 (7.9)
18 (90)
2 (10)
318–790 (481.45)
106.5 (25–400 mL)
152.5 (50–500 mL)
4–16 (7.4)

Table 3
Morbidity after surgical cytoreduction and HIPEC.
Morbidity

Gastrointestinal tract
Paralytic ileus
Anastomotic leak
Strangulated hernia
Hematologic
Blood transfusion
Wound hematoma
Leukopenia requiring intervention
Infections
Superﬁcial wound infection
Deep surgical site
Pulmonary
Pleural eﬀusions
Pneumothorax
Aspiration pneumonia
Renal
Acute Kidney Injury
Hospital Readmissions
Readmission < 30 days
Readmission > 30–90 days

Grade

Total (%)

I-II

III

IV

2
–
–

–
–
1

–
–
–

2
–
2

–
1
–

–
–
–

1
1

–
1

–
–

1
–
–

1
1
–

–
–
1

2

–

–

3 (15.0)

5 (25.0)

3 (15.0)

4 (20.0)

2 (10.0)

4 (20.0)
0 (0.0)

conﬁrmed to have either gross disease intraoperatively or microscopic
disease on ﬁnal pathology. This suggests that by not including a
planned hysterectomy or bilateral salpingo-oophorectomy at the time of
surgery, a less optimal debulking may occur. In addition, by involving
the gynecologic oncology service in preoperative assessment, patients
were counseled about the risks and beneﬁts of a total hysterectomy and
bilateral salpingo-oophorectomy before the procedure and were
3
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5. Conclusion
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